CHICAGO — In patients with refractory partial-onset seizures whose epilepsy is not controlled by antiepileptic drugs, the addition of eslicarbazepine acetate as monotherapy may improve quality of life.
The drug, commercially known as Aptiom (Sunovion), was tested in two randomized clinical trials to evaluate its effect on patient quality of life. The results were reported at the American Neurological Association 2015 Annual Meeting in Chicago.
Fulton F. Velez, MD, and colleagues administered the Quality of Life in Epilepsy-31 (QOLIE-31) survey to 226 patients who completed the two clinical trials. Changes in total QOLIE-31 scores and subscales (social functioning; medication effects; seizure worry; cognitive functioning; energy/fatigue; overall quality of life) from baseline to week 18 were compared to established minimal clinically-important differences (MCID).
In total, 211 patients completed the QOLIE-31 survey at baseline and week 18. Overall QOLIE-31 score significantly improved above MCID (6.72 vs. 5.19; P=0.043), with six of seven subscales improving above MCIDs. Three subscales showed a statistically significant improvement: social functioning (7.43 vs. 3.95; P=0.014); medication effects (9.00 vs. 5.00; P=0.022); and seizure worry (10.52 vs. 7.42; P=0.024). Three subscales did not show significant improvement: cognitive functioning (6.57 vs. 5.34; P=0.147); overall quality of life (7.13 vs. 6.42; P=0.266); and energy/fatigue (5.73 vs. 5.25; P=0.347).
Overall, patients who converted to eslicarbazepine acetate monotherapy experienced clinically-meaningful improvements in health-related quality of life.
- Bond TC et al. Abstract S319. Presented at: American Neurological Association Annual Meeting 2015; September 27-19, 2015; Chicago.